Growth Hormone Treatment in Non-growth Hormone-deficient Children
Overview
Affiliations
Until 1985 growth hormone (GH) was obtained from pituitary extracts, and was available in limited amounts only to treat severe growth hormone deficiency (GHD). With the availability of unlimited quantities of GH obtained from recombinant DNA technology, researchers started to explore new modalities to treat GHD children, as well as to treat a number of other non-GHD conditions. Although with some differences between different countries, GH treatment is indicated in children with Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, deletions/mutations of the SHOX gene, as well as in short children born small for gestational age and with idiopathic short stature. Available data from controlled trials indicate that GH treatment increases adult height in patients with Turner syndrome, in patients with chronic renal insufficiency, and in short children born small for gestational age. Patients with SHOX deficiency seem to respond to treatment similarly to Turner syndrome. GH treatment in children with idiopathic short stature produces a modest mean increase in adult height but the response in the individual patient is unpredictable. Uncontrolled studies indicate that GH treatment may be beneficial also in children with Noonan syndrome. In patients with Prader-Willi syndrome GH treatment normalizes growth and improves body composition and cognitive function. In any indication the response to GH seems correlated to the dose and the duration of treatment. GH treatment is generally safe with no major adverse effects being recorded in any condition.
Monogenic causes of familial short stature.
Plachy L, Dusatkova P, Amaratunga S, Neuman V, Sumnik Z, Lebl J Front Endocrinol (Lausanne). 2025; 15:1506323.
PMID: 39749023 PMC: 11693446. DOI: 10.3389/fendo.2024.1506323.
Intrauterine Growth References for Turkish Infants.
Atici A, Kanik A, Celik Y, Helvaci I Turk Arch Pediatr. 2024; 59(3):270-276.
PMID: 39140875 PMC: 11181255. DOI: 10.5152/TurkArchPediatr.2024.23313.
Analysis of children with familial short stature: who should be indicated for genetic testing?.
Plachy L, Petruzelkova L, Dusatkova P, Maratova K, Zemkova D, Elblova L Endocr Connect. 2023; 12(10).
PMID: 37561071 PMC: 10563636. DOI: 10.1530/EC-23-0238.
Growth charts in - and -related faciocraniosynostoses.
Ea C, Hennocq Q, Picard A, Polak M, Collet C, Legeai-Mallet L Bone Rep. 2022; 16:101524.
PMID: 35372644 PMC: 8965158. DOI: 10.1016/j.bonr.2022.101524.
Growth Hormone Dynamics among Children with Mixed Gonadal Dysgenesis (45,X/46,XY).
Das D Acta Endocrinol (Buchar). 2021; 17(1):117-123.
PMID: 34539919 PMC: 8417479. DOI: 10.4183/aeb.2021.117.